Target Price | $4.00 |
Price | $0.36 |
Potential |
1,011.82%
register free of charge
|
Number of Estimates | 2 |
2 Analysts have issued a price target ImmunoPrecise Antibodies Ltd 2026 .
The average ImmunoPrecise Antibodies Ltd target price is $4.00.
This is
1,011.82%
register free of charge
$4.99
1,285.79%
register free of charge
$3.02
737.85%
register free of charge
|
|
A rating was issued by 2 analysts: 2 Analysts recommend ImmunoPrecise Antibodies Ltd to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ImmunoPrecise Antibodies Ltd stock has an average upside potential 2026 of
1,011.82%
register free of charge
|
Apr '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 18.16 | 17.77 |
16.86% | 2.13% |
2 Analysts have issued a sales forecast ImmunoPrecise Antibodies Ltd 2025 . The average ImmunoPrecise Antibodies Ltd sales estimate is
This results in the following potential growth metrics:
Apr '24 |
2025 Estimates |
|
---|---|---|
EV/Sales | 0.51 |
Analyst | Rating | Action | Date |
---|---|---|---|
Benchmark |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 17 2024 |
Analyst Rating | Date |
---|---|
Locked
Benchmark:
Locked
➜
Locked
|
Apr 01 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 11 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 17 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.